ANRO
Alto Neuroscience Inc.
Company Overview
| Mkt Cap | $312.74M | Price | $15.13 |
| Volume | 217.79K | Change | +3.07% |
| P/E Ratio | -5.1 | Open | $14.96 |
| Revenue | -- | Prev Close | $14.68 |
| Net Income | $-61.4M | 52W Range | $1.60 - $16.49 |
| Div Yield | N/A | Target | $29.25 |
| Overall | 52 | Value | 60 |
| Quality | 34 | Technical | 63 |
No chart data available
About Alto Neuroscience Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Latest News
BTIG Keeps Their Buy Rating on Alto Neuroscience, Inc. (ANRO)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ANRO | $15.13 | +3.1% | 217.79K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |